Clinical Trials Logo

Clinical Trial Summary

This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06295731
Study type Interventional
Source Inhibrx, Inc.
Contact Study Director - Inhibrx
Phone 858-500-7833
Email clinicaltrials@inhibrx.com
Status Recruiting
Phase Phase 2/Phase 3
Start date May 14, 2024
Completion date May 2029

See also
  Status Clinical Trial Phase
Withdrawn NCT02211027 - Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA Phase 1
Recruiting NCT04083599 - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors Phase 1/Phase 2
Completed NCT03735628 - An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05891171 - Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers Phase 1
Recruiting NCT03546582 - SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma Phase 2
Not yet recruiting NCT06102447 - Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma N/A
Terminated NCT00911326 - Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma Phase 3
Completed NCT04220866 - Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) Phase 2
Withdrawn NCT03114280 - Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) Phase 1/Phase 2
Completed NCT02764593 - Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer Phase 1
Withdrawn NCT04849377 - RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC Phase 2
Completed NCT03268993 - Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer N/A
Recruiting NCT04284540 - Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma N/A
Recruiting NCT04080804 - Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer Phase 2
Active, not recruiting NCT04215978 - Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT03746431 - A Phase 1/2 Study of [225Ac]-FPI-1434 Injection Phase 1/Phase 2
Active, not recruiting NCT05249426 - A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer Phase 1
Not yet recruiting NCT05473156 - A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies Phase 1/Phase 2
Completed NCT02684253 - Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 2
Terminated NCT03276819 - A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC N/A